Trial Profile
BIBW 2992 Phase I Combination With Pemetrexed in Advanced Solid Tumours.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2015
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Pemetrexed
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 14 Nov 2012 Planned end date changed from 1 Oct 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 14 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.